← Retour au blog
tech 12 July 2026

The Shingles Vaccine May Reduce the Risk of Dementia

Recent studies suggest that the shingles vaccine may offer unexpected protection against dementia. Discover how this breakthrough could transform our approach to brain health.

Article inspired by the original source
The shingles vaccine may reduce the risk of dementia ↗ www.economist.com

A New Perspective on the Shingles Vaccine

The shingles vaccine, primarily known for its ability to prevent this painful viral infection, may have another ace up its sleeve. Recent studies suggest that this vaccine could also reduce the risk of developing dementia, a finding that could be a game-changer for millions of people worldwide.

Understanding the Link Between Shingles and Dementia

Shingles is caused by the varicella-zoster virus (VZV), the same virus responsible for chickenpox. After chickenpox, the virus remains dormant in the body and can reactivate years later as shingles. Researchers have discovered that this reactivation may also impact the brain, potentially contributing to inflammation and brain damage associated with dementia.

A study conducted by the University of Oxford found that individuals vaccinated against shingles had a 20% lower risk of dementia compared to those who were not vaccinated. This risk reduction is significant, especially considering that, according to the WHO, over 55 million people currently live with dementia worldwide.

Possible Mechanisms Behind This Protection

Although the exact mechanism remains to be elucidated, several hypotheses are proposed. One theory is that vaccination stimulates the immune system in a way that reduces systemic inflammation, a known risk factor for dementia. Another hypothesis is that the vaccine might directly prevent VZV reactivation in the brain, thus limiting neuronal damage.

Implications for Public Health

If the results are confirmed by further studies, the shingles vaccine could become an essential tool not only for preventing shingles but also for protecting against dementia. This could lead to increased vaccination rates, particularly among older adults who are at higher risk for both shingles and dementia.

In the United States, the CDC already recommends the shingles vaccine for adults aged 50 and over. With this new perspective, public health policymakers might consider expanding this recommendation to include a broader audience or intensifying vaccination campaigns.

Economic Potential

Reducing the risk of dementia through vaccination could also have significant economic implications. Dementia is a leading cause of dependency and healthcare costs among the elderly. By delaying or preventing its onset, substantial savings could be realized in healthcare expenditures, while improving patients' quality of life.

Conclusion

The discovery of the shingles vaccine's protective potential against dementia is promising. It paves the way for innovative approaches in preventing neurodegenerative diseases. As research progresses, it is crucial to continue exploring these links to offer better public health strategies.

Let's discuss your project in 15 minutes.

shingles vaccine dementia risk public health neurodegenerative diseases vaccination benefits
Deepthix newsletter · 100% AI · every Monday 8am

An AI agent reads tech for you.

Our AI agent scans ~200 sources per week and ships the best articles to your inbox Monday 8am. Free. One click to unsubscribe.

Visit the newsletter page →

Want to automate your operations?

Let's talk about your project in 15 minutes.

Book a call